600557 康缘药业
已收盘 06-24 15:00:00
资讯
新帖
简况
康缘药业（600557）披露前十大股东持股情况，6月22日股价下跌1.94%
证券之星 · 06-22 22:38
康缘药业（600557）披露前十大股东持股情况，6月22日股价下跌1.94%
股市必读：康缘药业（600557）6月1日董秘有最新回复
证券之星 · 06-02
股市必读：康缘药业（600557）6月1日董秘有最新回复
康缘药业：公司中药新药研发一直围绕病毒性感染、心脑血管、妇科、骨伤科、消化/肾病等优势领域
证券之星 · 06-01
康缘药业：公司中药新药研发一直围绕病毒性感染、心脑血管、妇科、骨伤科、消化/肾病等优势领域
康缘药业：公司在化药和生物药领域，已储备多个研发管线
证券之星 · 06-01
康缘药业：公司在化药和生物药领域，已储备多个研发管线
康缘药业：热毒宁注射液被列入《中医药治疗埃博拉出血热专家指导意见》
证券之星 · 05-29
康缘药业：热毒宁注射液被列入《中医药治疗埃博拉出血热专家指导意见》
股市必读：康缘药业(600557)股东户数4.22万户，较上期减少1.33%
证券之星 · 05-06
股市必读：康缘药业(600557)股东户数4.22万户，较上期减少1.33%
每周股票复盘：康缘药业（600557）Q1营收净利双降
证券之星 · 05-02
每周股票复盘：康缘药业（600557）Q1营收净利双降
康缘药业（600557）披露2026年第一季度报告，4月29日股价上涨0.14%
证券之星 · 04-29
康缘药业（600557）披露2026年第一季度报告，4月29日股价上涨0.14%
图解康缘药业一季报：第一季度单季净利润同比下降4.96%
证券之星 · 04-29
图解康缘药业一季报：第一季度单季净利润同比下降4.96%
每周股票复盘：康缘药业（600557）2025年净利降22.44%
证券之星 · 04-26
每周股票复盘：康缘药业（600557）2025年净利降22.44%
股市必读：康缘药业年报 - 第四季度单季净利润同比增长27.60%
证券之星 · 04-24
股市必读：康缘药业年报 - 第四季度单季净利润同比增长27.60%
康缘药业新注册《中药均化计算软件V1.0》项目的软件著作权
证券之星 · 04-23
康缘药业新注册《中药均化计算软件V1.0》项目的软件著作权
图解康缘药业年报：第四季度单季净利润同比增长27.60%
证券之星 · 04-23
图解康缘药业年报：第四季度单季净利润同比增长27.60%
康缘药业(600557.SH)收到青参通络颗粒临床试验批准通知书
智通财经 · 04-19
康缘药业(600557.SH)收到青参通络颗粒临床试验批准通知书
辉煌不再：康缘药业，从中药明星到十字路口
蓝鲸财经 · 03-19
辉煌不再：康缘药业，从中药明星到十字路口
康缘药业最新公告：收到黑黄赤珠颗粒临床试验批准通知书
证券之星 · 02-25
康缘药业最新公告：收到黑黄赤珠颗粒临床试验批准通知书
康缘药业新注册《CIP清洁系统排污口视觉识别系统V1.0》等2个项目的软件著作权
证券之星 · 02-16
康缘药业新注册《CIP清洁系统排污口视觉识别系统V1.0》等2个项目的软件著作权
康缘药业公布国际专利申请：“一类三并环化合物，其制备方法及其用途”
证券之星 · 02-15
康缘药业公布国际专利申请：“一类三并环化合物，其制备方法及其用途”
康缘药业新注册《AGV智能监控与调度系统1.0》等4个项目的软件著作权
证券之星 · 02-14
康缘药业新注册《AGV智能监控与调度系统1.0》等4个项目的软件著作权
康缘药业（600557）披露运脾化痰通窍颗粒临床试验获批公告，1月26日股价上涨2.0%
证券之星 · 01-26
康缘药业（600557）披露运脾化痰通窍颗粒临床试验获批公告，1月26日股价上涨2.0%
加载更多
公司概况
公司名称：
江苏康缘药业股份有限公司
所属行业：
医药制造业
上市日期：
2002-09-18
主营业务：
江苏康缘药业股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是注射类产品、口服类产品、外用类产品。公司是国家技术创新示范企业、国家重点高新技术企业、国家创新型试点企业、国家知识产权示范企业，全国制药工业百强企业。
发行价格：
7.00
{"stockData":{"symbol":"600557","market":"SH","secType":"STK","nameCN":"康缘药业","latestPrice":11.62,"timestamp":1782284400000,"preClose":11.79,"halted":0,"volume":5294805,"delay":0,"changeRate":-0.0144,"floatShares":566000000,"shares":566000000,"eps":0.5296,"marketStatus":"已收盘","change":-0.17,"latestTime":"06-24 15:00:00","open":11.91,"high":11.98,"low":11.58,"amount":62279400,"amplitude":0.0339,"askPrice":11.63,"askSize":196,"bidPrice":11.62,"bidSize":430,"shortable":0,"etf":0,"ttmEps":0.5296,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782351000000},"marketStatusCode":5,"adr":0,"adjPreClose":11.79,"symbolType":"stock","openAndCloseTimeList":[[1782264600000,1782271800000],[1782277200000,1782284400000]],"highLimit":12.97,"lowLimit":10.61,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":566158806,"isCdr":false,"pbRate":1.34,"roa":"--","peRate":21.941088,"roe":"1.63%","epsLYR":0.54,"committee":0.167785,"marketValue":6579000000,"turnoverRate":0.0094,"status":1,"floatMarketCap":6579000000},"requestUrl":"/m/hq/s/600557/","defaultTab":"news","newsList":[{"id":"2645073406","title":"康缘药业（600557）披露前十大股东持股情况，6月22日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645073406?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:38","pubTimestamp":1782139103,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，康缘药业报收于11.6元，较前一交易日下跌1.94%，最新总市值为65.67亿元。该股当日开盘11.78元，最高11.78元，最低11.29元，成交额达6179.17万元，换手率为0.95%。公告显示，截至2026年6月17日股东会股权登记日，公司前十大股东及前十大无限售条件股东的持股情况。其中，江苏康缘集团有限责任公司持股176,173,467股，占比31.12%，为第一大股东。连云港康贝尔医疗器械有限公司、肖伟等位列其后。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200039062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640969870","title":"股市必读：康缘药业（600557）6月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640969870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640969870?lang=zh_cn&edition=full","pubTime":"2026-06-02 02:09","pubTimestamp":1780337354,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，康缘药业报收于12.86元，下跌0.39%，换手率0.79%，成交量4.47万手，成交额5740.72万元。董秘最新回复投资者： 公司应当向同城的恒瑞和豪森学习，逐步收缩中药业务，向化学药和生物药倾斜，另外，请贵司说明，为什么中新医药合并报表后研发费用反而不见增加，是不是研发费用这一项目有什么会计上的特殊处理方法？现阶段中药业务仍然是公司主营业务和现金流，确保公司运营和研发投入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200001687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","600557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640958083","title":"康缘药业：公司中药新药研发一直围绕病毒性感染、心脑血管、妇科、骨伤科、消化/肾病等优势领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2640958083","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640958083?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:15","pubTimestamp":1780308920,"startTime":"0","endTime":"0","summary":"证券之星消息，康缘药业06月01日在投资者关系平台上答复投资者关心的问题。强烈建议公司梳理中药研发管线，将一些中药不占优势，疗效不明显的非重点科室的项目中止。公司中药新药研发一直围绕病毒性感染、心脑血管、妇科、骨伤科、消化/肾病等优势领域，以十年为一个研发周期，合理布局管线，确保研发成果持续产出，为营销提供丰富产品组合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100029554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640958701","title":"康缘药业：公司在化药和生物药领域，已储备多个研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2640958701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640958701?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:13","pubTimestamp":1780308802,"startTime":"0","endTime":"0","summary":"证券之星消息，康缘药业06月01日在投资者关系平台上答复投资者关心的问题。公司在化药和生物药领域，已储备多个研发管线，覆盖多个治疗领域，构建中长期产品梯队，高起点的布局，确保未来创新药不断产出。现阶段中药业务仍然是公司主营业务和现金流，确保公司运营和研发投入。在收购中新医药后，公司生物药领域的研发投入有所加大。公司会结合行业趋势与自身实际，合理配置研发资源。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100029398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600557","BK0028","159839","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639862921","title":"康缘药业：热毒宁注射液被列入《中医药治疗埃博拉出血热专家指导意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2639862921","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639862921?lang=zh_cn&edition=full","pubTime":"2026-05-29 18:24","pubTimestamp":1780050280,"startTime":"0","endTime":"0","summary":"证券之星消息，康缘药业(600557)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：康缘药业有没有治疗或缓解埃博拉的药？热毒宁注射液是不是列入《中医药治疗埃博拉出血热专家指导意见》？康缘药业回复：尊敬的投资者，您好！热毒宁注射液被列入2014年由国家中医药管理局办公室印发的《中医药治疗埃博拉出血热专家指导意见（第一版）》，该文件属于中医药治疗埃博拉出血热的指导性意见，目前公司暂无专门用于治疗或缓解埃博拉病毒的药物。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900035445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600557","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633920984","title":"股市必读：康缘药业(600557)股东户数4.22万户，较上期减少1.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633920984","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633920984?lang=zh_cn&edition=full","pubTime":"2026-05-06 05:46","pubTimestamp":1778017573,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，康缘药业报收于13.48元，下跌3.37%，换手率1.96%，成交量11.08万手，成交额1.5亿元。来自股本股东变化：截至2026年3月31日，公司股东户数环比下降1.33%，户均持股数量上升至1.34万股。股本股东变化股东户数变动截至2026年3月31日，公司股东户数为4.22万户，较2025年12月31日减少568.0户，减幅为1.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600557","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632234666","title":"每周股票复盘：康缘药业（600557）Q1营收净利双降","url":"https://stock-news.laohu8.com/highlight/detail?id=2632234666","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632234666?lang=zh_cn&edition=full","pubTime":"2026-05-02 06:18","pubTimestamp":1777673892,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，康缘药业报收于13.48元，较上周的14.21元下跌5.14%。本周关注点来自业绩披露要点：康缘药业2026年一季报显示，一季度主营收入8.31亿元，同比下降5.27%；归母净利润7927.59万元，同比下降4.96%。股本股东变化股东户数变动截至2026年3月31日，康缘药业股东户数为4.22万户，较2025年12月31日减少568户，减幅1.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631554368","title":"康缘药业（600557）披露2026年第一季度报告，4月29日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631554368","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631554368?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:27","pubTimestamp":1777472858,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，康缘药业报收于13.95元，较前一交易日上涨0.14%，最新总市值为78.98亿元。该股当日开盘13.91元，最高14.06元，最低13.87元，成交额达6202.29万元，换手率为0.78%。近日，江苏康缘药业股份有限公司披露《2026年第一季度报告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900069325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631511329","title":"图解康缘药业一季报：第一季度单季净利润同比下降4.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631511329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631511329?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:24","pubTimestamp":1777465445,"startTime":"0","endTime":"0","summary":"证券之星消息，康缘药业2026年一季报显示，一季度公司主营收入8.31亿元，同比下降5.27%；归母净利润7927.59万元，同比下降4.96%；扣非净利润7202.35万元，同比下降12.17%；负债率26.06%，投资收益264.44万元，财务费用5.07万元，毛利率74.97%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900061980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630802861","title":"每周股票复盘：康缘药业（600557）2025年净利降22.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630802861","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630802861?lang=zh_cn&edition=full","pubTime":"2026-04-26 04:38","pubTimestamp":1777149490,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，康缘药业报收于14.21元，较上周的13.92元上涨2.08%。本周，康缘药业4月23日盘中最高价报14.66元。康缘药业当前最新总市值80.45亿元，在中药板块市值排名28/66，在两市A股市值排名2423/5200。股本股东变化截至2026年3月31日，康缘药业股东户数为4.22万户，较2025年12月31日减少568.0户，减幅1.33%。业绩披露要点康缘药业2025年主营收入32.93亿元，同比下降15.52%；归母净利润3.04亿元，同比下降22.44%；扣非净利润2.17亿元，同比下降40.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","600557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629485720","title":"股市必读：康缘药业年报 - 第四季度单季净利润同比增长27.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629485720","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629485720?lang=zh_cn&edition=full","pubTime":"2026-04-24 03:42","pubTimestamp":1776973341,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日康缘药业披露，截至2026年3月31日公司股东户数为4.22万户，较12月31日减少568.0户，减幅为1.33%。江苏康缘药业股份有限公司2025年度利润分配方案公告江苏康缘药业股份有限公司2025年度拟不进行现金分红，不送红股，不进行资本公积金转增股本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400009225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629242600","title":"康缘药业新注册《中药均化计算软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2629242600","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629242600?lang=zh_cn&edition=full","pubTime":"2026-04-23 02:51","pubTimestamp":1776883869,"startTime":"0","endTime":"0","summary":"证券之星消息，近日康缘药业（600557）新注册了《中药均化计算软件V1.0》项目的软件著作权。今年以来康缘药业新注册软件著作权7个，较去年同期增加了250%。结合公司2025年年报财务数据，2025年公司在研发方面投入了6.08亿元，同比减4.78%。通过天眼查大数据分析，江苏康缘药业股份有限公司共对外投资了19家企业，参与招投标项目7260次；财产线索方面有商标信息472条，专利信息1044条，著作权信息46条；此外企业还拥有行政许可700个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300005138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159180","BK0028","BK0188","600557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629029937","title":"图解康缘药业年报：第四季度单季净利润同比增长27.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629029937","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629029937?lang=zh_cn&edition=full","pubTime":"2026-04-23 01:04","pubTimestamp":1776877477,"startTime":"0","endTime":"0","summary":"证券之星消息，康缘药业2025年年报显示，当年度公司主营收入32.93亿元，同比下降15.52%；归母净利润3.04亿元，同比下降22.44%；扣非净利润2.17亿元，同比下降40.18%；其中2025年第四季度，公司单季度主营收入9.5亿元，同比上升20.15%；单季度归母净利润1.04亿元，同比上升27.6%；单季度扣非净利润5713.73万元，同比下降26.76%；负债率26.96%，投资收益1024.31万元，财务费用-420.55万元，毛利率71.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300002146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628663107","title":"康缘药业(600557.SH)收到青参通络颗粒临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628663107","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628663107?lang=zh_cn&edition=full","pubTime":"2026-04-19 15:39","pubTimestamp":1776584379,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康缘药业(600557.SH)发布公告，公司近日收到国家药品监督管理局签发的青参通络颗粒《药物临床试验批准通知书》。青参通络颗粒审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2026年01月28日受理的青参通络颗粒临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意本品开展用于类风湿关节炎湿热痹阻证的确证性临床试验(Ⅲ期临床试验)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","600557","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620228758","title":"辉煌不再：康缘药业，从中药明星到十字路口","url":"https://stock-news.laohu8.com/highlight/detail?id=2620228758","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620228758?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:45","pubTimestamp":1773924338,"startTime":"0","endTime":"0","summary":"截至 3 月 13 日收盘，康缘药业市值约80 亿元，较历史高点大幅缩水。业绩持续下滑、核心产品遇阻、转型步履维艰，康缘药业正站在发展的关键十字路口。1996 年企业完成改制，2002 年康缘药业成功登陆上交所，正式迈入资本市场。热毒宁颗粒能否获批、新产品能否接棒、新战略能否落地，将决定康缘药业能否走出十字路口，重回增长轨道。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773845140916726056","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["600557","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614088341","title":"康缘药业最新公告：收到黑黄赤珠颗粒临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614088341","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614088341?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:21","pubTimestamp":1772014892,"startTime":"0","endTime":"0","summary":"康缘药业(600557.SH)公告称，近日收到国家药品监督管理局签发的黑黄赤珠颗粒《药物临床试验批准通知书》，同意开展用于慢性心力衰竭的临床试验。该药品功能主治为益气活血、通阳利水，适用于缺血性心脏病引起的慢性心力衰竭气阳虚血瘀水泛证。黑黄赤珠颗粒的研发预期具有明显的临床价值和良好的市场前景。但需完成临床试验，并经国家药监局审评、审批通过后方可生产上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500031682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600557","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611178456","title":"康缘药业新注册《CIP清洁系统排污口视觉识别系统V1.0》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2611178456","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611178456?lang=zh_cn&edition=full","pubTime":"2026-02-16 01:38","pubTimestamp":1771177095,"startTime":"0","endTime":"0","summary":"证券之星消息，近日康缘药业新注册了2个项目的软件著作权，包括《CIP清洁系统排污口视觉识别系统V1.0》、《中药材醇沉过程智能在线监测系统V1.0》等。今年以来康缘药业新注册软件著作权6个，较去年同期增加了500%。通过天眼查大数据分析，江苏康缘药业股份有限公司共对外投资了19家企业，参与招投标项目7266次；财产线索方面有商标信息467条，专利信息1064条，著作权信息42条；此外企业还拥有行政许可688个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021600000041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","600557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611149571","title":"康缘药业公布国际专利申请：“一类三并环化合物，其制备方法及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2611149571","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611149571?lang=zh_cn&edition=full","pubTime":"2026-02-15 05:13","pubTimestamp":1771103590,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示康缘药业（600557）公布了一项国际专利申请，专利名为“一类三并环化合物，其制备方法及其用途”，专利申请号为PCT/CN2025/113664，国际公布日为2026年2月12日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来康缘药业已公布的国际专利申请1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.47亿元，同比减32.26%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600557","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611162630","title":"康缘药业新注册《AGV智能监控与调度系统1.0》等4个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2611162630","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611162630?lang=zh_cn&edition=full","pubTime":"2026-02-14 01:56","pubTimestamp":1771005374,"startTime":"0","endTime":"0","summary":"证券之星消息，近日康缘药业新注册了4个项目的软件著作权，包括《AGV智能监控与调度系统1.0》、《中药带式干燥批次差异分析可视化系统1.0》、《中药材质量在线预测分析系统1.0》、《中药材工艺参数自动调控系统1.0》等。今年以来康缘药业新注册软件著作权4个，较去年同期增加了300%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021400000492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","600557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606249953","title":"康缘药业（600557）披露运脾化痰通窍颗粒临床试验获批公告，1月26日股价上涨2.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606249953","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606249953?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:48","pubTimestamp":1769438905,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，康缘药业报收于15.32元，较前一交易日上涨2.0%，最新总市值为86.74亿元。近日，江苏康缘药业股份有限公司发布关于收到运脾化痰通窍颗粒临床试验批准通知书的公告。公告显示，公司收到国家药品监督管理局签发的运脾化痰通窍颗粒《药物临床试验批准通知书》，同意该药品开展用于儿童腺样体肥大脾虚痰阻证的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600036736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600557","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782340088969,"stockEarnings":[{"period":"1week","weight":-0.0219},{"period":"1month","weight":-0.0561},{"period":"3month","weight":-0.1163},{"period":"6month","weight":-0.1857},{"period":"1year","weight":-0.2289},{"period":"ytd","weight":-0.1765}],"compareEarnings":[{"period":"1week","weight":0.0007},{"period":"1month","weight":-0.0101},{"period":"3month","weight":0.057},{"period":"6month","weight":0.0371},{"period":"1year","weight":0.2018},{"period":"ytd","weight":0.0358}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏康缘药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42174人(较上一季度减少1.33%)","perCapita":"13424股","listingDate":"2002-09-18","address":"江苏省连云港市连云区经济技术开发区江宁工业城","registeredCapital":"56615万元","survey":" 江苏康缘药业股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是注射类产品、口服类产品、外用类产品。公司是国家技术创新示范企业、国家重点高新技术企业、国家创新型试点企业、国家知识产权示范企业，全国制药工业百强企业。","listedPrice":7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康缘药业(600557)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康缘药业(600557)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康缘药业,600557,康缘药业股票,康缘药业股票老虎,康缘药业股票老虎国际,康缘药业行情,康缘药业股票行情,康缘药业股价,康缘药业股市,康缘药业股票价格,康缘药业股票交易,康缘药业股票购买,康缘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康缘药业(600557)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康缘药业(600557)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}